Terminated PHASE2 INTERVENTIONAL 3-arm NCT02387957

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Sponsor: Ophthotech Corporation

Conditions Age-Related Macular Degeneration

Interventions Fovista® aflibercept bevacizumab ranibizumab

Updated 11 times since 2017 Last updated: Oct 19, 2024 Started: Apr 26, 2016 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Ophthotech Corporation

More terminations from Ophthotech Corporation

Other Age-Related Macular Degeneration trials with similar outcome

Browse all Age-Related Macular Degeneration trials

Listed as NCT02387957, this PHASE2 trial focuses on Age-Related Macular Degeneration and remains terminated or withdrawn. Sponsored by Ophthotech Corporation, it has been updated 11 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Nov 2024 — Present [monthly]

Terminated PHASE2
Sep 2024 — Nov 2024 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Mar 2024 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Mar 2024 [monthly]

Terminated PHASE2

▶ Show 6 earlier versions

Feb 2020 — Jan 2021 [monthly]

Terminated PHASE2
Apr 2019 — Feb 2020 [monthly]

Terminated PHASE2
Jun 2018 — Apr 2019 [monthly]

Terminated PHASE2
May 2017 — Jun 2018 [monthly]

Terminated PHASE2
Feb 2017 — May 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ophthotech Corporation

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Amarillo, United States , Augusta, United States , Beverly Hills, United States , Boston, United States , Cleveland, United States , Fort Lauderdale, United States , Fort Myers, United States , Huntingdon Valley, United States , Ladson, United States and 14 more locations